KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer. PMID 41235190 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Closed-loop temperature management with internet of things technology support in elderly laparoscopic rectal cancer surgery: A randomised controlled trial. PMID 41231776 · PLoS One · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol. PMID 41210271 · Front Sports Act Living · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study. PMID 41208989 · Front Immunol · 2025 The study is a non-oncology, non-randomized observational cohort study comparing the risk of uveitis in patients with spondyloarthritis and psoriatic diseases treated with Janus kinase inhibitors versus tumor necrosis factor inhibitors. While it includes drug interventions and a time-to-event endpoint, it does not meet the core oncology or randomized trial criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial. PMID 41200184 · Front Immunol · 2025 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ethical issues in a cluster randomised controlled trial for evaluating effectiveness of screening for breast cancer by clinical breast examination in India. PMID 41195487 · Indian J Med Ethics · 2025 The record is an ethical analysis of a cluster randomized screening trial, not a report of a drug-containing oncology Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial. PMID 41185705 · Drug Des Devel Ther · 2025 The study is a randomized, controlled trial in breast cancer patients investigating a drug intervention (esketamine) for postoperative depression. However, it is not explicitly a Phase III or definitive randomized trial as required, and the primary efficacy endpoint is a depression score (HAMD-17), not a time-to-event oncology endpoint like overall survival or progression-free survival.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimistic Bias and Personality Factors in Adherence to Oral Anticancer Treatments in Metastatic Breast Cancer: A Retrospective Analysis of Data From a Randomized Controlled Trial. PMID 41172984 · Cancer Control · 2025 The study is a secondary analysis of an RCT focusing on adherence and psychological factors, not the original trial report. It does not report on a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. PMID 41164107 · Front Mol Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty: A Multicenter Randomized Controlled Trial Protocol. PMID 41146865 · Clin Interv Aging · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Baofukang suppository on the relative indexes of epithelial mesenchymal transformation of tumor cells and prognosis in patients with cervical cancer. PMID 41139264 · Pak J Pharm Sci · 2025 The record describes a randomized trial in cervical cancer patients with a drug-containing intervention, but the abstract reports only surrogate/biomarker outcomes (EMT markers, cytokines, immune cells) and safety. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analysis. The phase is not explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. PMID 41122636 · Front Oncol · 2025 The report presents pre-specified secondary endpoints of health-related quality of life (PROs) from a phase 3 randomized trial, but does not include primary or key secondary time-to-event efficacy endpoints such as OS, PFS, or DFS. The analysis is focused on patient-reported outcomes, which are excluded from the cohort criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study. PMID 41122314 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes of endoscopic third ventriculostomy in comparison to ventriculoperitoneal shunt in obstructive hydrocephalus - A randomized controlled trial. PMID 41112363 · Surg Neurol Int · 2025 The study is not oncology-focused (obstructive hydrocephalus) and lacks a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial. PMID 41084724 · J Blood Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Metformin and estrogen modulation in LABC with T2DM: A 36-month randomized trial. PMID 41079227 · Open Med (Wars) · 2025 The study is a randomized drug trial in human oncology with time-to-event endpoints and original results. However, it is not eligible because the trial phase is not established as Phase III/IIIb or Phase II/III (a required criterion), and the design is not a standard definitive randomized controlled trial as per the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol. PMID 41064168 · Front Psychol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety & efficacy of thulium laser endoscopic en bloc resection versus conventional trans urethral resection of bladder tumors, for treatment of non muscle invasive bladder tumors: A prospective randomized trial. PMID 41050386 · Arab J Urol · 2025 Eligibility criteria not met: study lacks a drug-containing intervention (compares surgical techniques) and lacks a time-to-event primary/key secondary efficacy endpoint (recurrence rate is a categorical outcome at 12 months, not a survival/recurring event analyzed with KM/HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial. PMID 41050349 · Front Surg · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial. PMID 41042207 · Cancer Control · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Comparison of Postoperative Analgesic Effects of Intravenous versus Perineural Dexamethasone Injection Combined with Ropivacaine in Thoracoscopy-Guided Thoracic Paravertebral Block for Thoracoscopic Radical Lung Cancer Resection: A Prospective Randomized Controlled Trial. PMID 41017807 · Drug Des Devel Ther · 2025 Study is a randomized, prospective, human oncology trial, but it lacks a drug-containing intervention (the intervention is anesthetic technique and analgesic adjuvant) and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier analysis or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. PMID 40980453 · Neurooncol Adv · 2025 This publication is a methodological study that applies and validates clinical benefit assessment scales (ESMO-MCBS, ASCO, Neuro-MCBS) to a collection of existing neuro-oncology studies. It is not an original result report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. The abstract describes the development and testing of a scoring tool, not the presentation of trial-specific efficacy data.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DEHyART trial: Study protocol for phase 2 randomised controlled study assessing the role of dose escalation using [18F] fluoromisonidazole positron emission tomography/computed tomography in head and neck cancers. PMID 40949474 · Ecancermedicalscience · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect analysis of percutaneous catheter drainage combined with radiofrequency ablation in the treatment of mixed thyroid nodules. PMID 40937415 · Front Endocrinol (Lausanne) · 2025 The study is a randomized trial on benign thyroid nodules (non-malignant), uses a non-drug intervention (radiofrequency ablation and catheter drainage), and reports outcomes such as tumor size, treatment duration, pain, hoarseness, and recurrence counts without Kaplan-Meier or HR analysis, failing to meet eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Photodynamic Therapy and 5-Fluorouracil Cream versus Surgical Excision in Treatment of Bowen's Disease: A Trial-Based Economic Evaluation. PMID 40934140 · Dermatology · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. PMID 40918097 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Strategy-based cognitive rehabilitation for childhood brain tumour: Protocol for an acceptability and feasibility trial of the Fatigue, Learning, and Memory Enrichment (FLaME) intervention. PMID 40917737 · NIHR Open Res · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial. PMID 40907021 · Cancer Control · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013). PMID 40901464 · Front Immunol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Study protocol for a randomized controlled clinical trial of a multifaceted cognitive training program using video games in childhood cancer survivors. PMID 40892751 · PLoS One · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness of radiofrequency and exercise-based rehabilitation on symptoms associated with pelvic floor dysfunction in breast cancer patients: A study protocol. PMID 40880350 · PLoS One · 2025 The record is a study protocol, not a formal result report. It lacks reported efficacy data. Furthermore, it does not meet core eligibility criteria: the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, the interventions are non-drug only (radiofrequency and pelvic floor muscle training), and the primary endpoints are not time-to-event efficacy measures (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis. PMID 40875656 · PLoS One · 2025 The record describes a randomized trial in rheumatoid arthritis, not oncology. While it is a human randomized trial with drug interventions and reports survival analysis for remission, the disease is non-oncologic and the endpoint (time to remission in RA) is not an oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The anti-inflammatory and antioxidant effects of astaxanthin as an adjunctive therapy in community-acquired pneumonia: a randomized controlled trial. PMID 40852606 · Front Pharmacol · 2025 The study is not an oncology trial; it is a randomized controlled trial for community-acquired pneumonia, a non-malignant condition. The primary endpoint is inflammatory markers, not a time-to-event efficacy outcome. The intervention is a supplement (astaxanthin), not a cancer drug. Therefore, it is excluded on multiple grounds.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact on outcomes of ultra hypofractionation or hypofractionation regimens and proton or Xrays therapy in a phase III randomized controlled trial MC1635. PMID 40842574 · Front Oncol · 2025 The record is a Phase III randomized controlled trial in oncology, but it lacks a specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and the intervention appears to be radiation therapy (hypofractionation/proton vs. X-ray) without a drug component, making it ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40823083 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The efficacy of early progressive resistance exercise in the postoperative management of pancreaticoduodenectomy for pancreatic cancer: a randomized controlled trial. PMID 40822270 · Front Surg · 2025 The study is a randomized controlled trial in pancreatic cancer surgery evaluating an exercise intervention, but it lacks a drug intervention and does not report any time-to-event efficacy endpoints like OS, PFS, DFS, etc. It focuses on recovery metrics and quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial. PMID 40800123 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Controlled Trial Comparative Study in Powered and Manual Stapler in Low Anterior Resection of Rectal Cancer. PMID 40798889 · Asian J Endosc Surg · 2025 The study is a randomized controlled trial in rectal cancer patients comparing two surgical staplers, not a drug intervention. It does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR; the primary outcome is anastomotic leakage (a complication), with logistic regression analysis. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355). PMID 40791599 · Front Immunol · 2025 The study is a retrospective real-world analysis and does not meet the requirement for a Phase III/IIIb or Phase II/III randomized trial. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients. PMID 40777124 · Front Oncol · 2025 The record describes a subgroup analysis from a Phase III randomized trial in NSCLC evaluating neoadjuvant chemoimmunotherapy cycles. While it is oncologic, human, randomized, Phase III, and drug-intervening, the primary endpoint reported is pathological complete response (pCR), a binary pathological outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The analysis is explicitly a subgroup analysis based on ctDNA-MRD status. Therefore, it does not meet the inclusion criteria for a time-to-event primary/key secondary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of endoscopic and endoscope-assisted microscopic transsphenoidal surgery for pituitary adenoma resection: a prospective randomized study. PMID 40766292 · Front Endocrinol (Lausanne) · 2025 Study compares surgical techniques for pituitary adenoma, lacks drug intervention, and does not report time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional study. PMID 40765840 · BMJ Oncol · 2025 This is a cross-sectional methodological study analyzing control arms of trials, not an original report of a single trial's efficacy results. It does not present time-to-event efficacy data (OS, PFS, etc.) from a specific trial. The drug intervention criterion cannot be established from this secondary analysis.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Acceptability and implementation potential of a health literacy intervention to increase colorectal cancer screening in deprived areas: A qualitative study of patients and general practitioners participating in a cluster randomized controlled trial. PMID 40763131 · PLoS One · 2025 The record is a qualitative study of a health literacy intervention for colorectal cancer screening. While it is from a randomized controlled trial (cluster RCT), it does not meet key eligibility criteria: it lacks a drug-containing intervention, no time-to-event efficacy endpoint is reported, and the phase is not established as Phase III/IIIb or Phase II/III. The study reports patient and provider acceptability, not efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploratory unsupervised machine learning of angiogenesis biomarkers in a phase II advanced cervical cancer trial of radiochemotherapy with or without neoadjuvant chemotherapy. PMID 40743651 · Clinics (Sao Paulo) · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin. PMID 40740570 · Med J Islam Repub Iran · 2025 The study is a non-randomized controlled trial (explicitly stated in title and methods), which excludes it from being a randomized trial. The phase is not specified, and there is no indication it is Phase III/IIIb. The primary endpoint is pathological complete response (pCR), which is not a time-to-event efficacy endpoint. No time-to-event data (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier curves, or hazard ratios are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated radiotherapy for head and neck squamous cell carcinoma. PMID 40737737 · Cancer Radiother · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effectiveness of Remote High-Intensity Aerobic Interval Training on Quality of Life and Physical Health in Breast Cancer Survivors: Two Years Follow-Up. PMID 40735810 · Integr Cancer Ther · 2025 Study is an oncology, human, randomized controlled trial reporting original results. However, it does not meet key eligibility criteria: the intervention is non-drug-only (exercise), there is no time-to-event efficacy endpoint (OS, PFS, etc.), the phase is not explicitly stated as III/IIIb, and the primary endpoint is quality of life/physical health (not time-to-event efficacy).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of a Care Plan Based on the Multi-Theory Model in Reducing Fear of Disease Progression and Improving Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial. PMID 40735051 · Breast Cancer (Dove Med Press) · 2025 The study is a randomized controlled trial in breast cancer patients receiving adjuvant chemotherapy, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR results. The primary outcomes are psychological and quality-of-life measures (fear of progression, quality of life, self-management efficacy). The phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pancreatoduodenectomy versus total pancreatectomy and simultaneous intraportal islet autotransplantation for periampullary cancer at high-risk of postoperative pancreatic fistula (XANDTX-trial): Protocol of a randomized controlled pilot trial. PMID 40720532 · PLoS One · 2025 Excluded because it is a protocol (no results), lacks a drug-containing intervention, and does not establish a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of anlotinib combined with docetaxel versus single docetaxel as second-line treatment beside radiotherapy for advanced non-small cell lung cancer: Efficacy and safety. PMID 40679002 · Pak J Pharm Sci · 2025 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (PFS). However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, MeSH). The metadata indicates 'needs_review' with 'phase3_evidence_unclear'. Per the adjudication rules, the phase must be explicitly established; it cannot be inferred or assumed. Therefore, the required criterion of phase3_or_definitive cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -